v3.25.1
Commitments and Contingencies (Details)
$ in Thousands
1 Months Ended
Apr. 16, 2025
Apr. 07, 2025
USD ($)
Aug. 27, 2024
Jul. 03, 2024
litigationCase
Dec. 15, 2023
litigationCase
Feb. 24, 2023
Feb. 15, 2023
litigationCase
Jan. 03, 2023
Jul. 21, 2022
Jun. 22, 2022
litigationCase
Jun. 23, 2020
litigationCase
Mar. 31, 2023
patent
Feb. 28, 2023
patent
Jul. 31, 2021
patent
Jun. 30, 2021
patent
Mar. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Jun. 07, 2022
patent
May 13, 2021
patent
Loss Contingencies [Line Items]                                      
Accrued litigation settlement expenses | $                               $ 172,000 $ 0    
Subsequent Event                                      
Loss Contingencies [Line Items]                                      
Settlement amount | $   $ 145,000                                  
Teamsters and GEHA Lawsuits                                      
Loss Contingencies [Line Items]                                      
Number of lawsuits filed | litigationCase                     2                
Avadel Pharmaceuticals plc Lawsuit                                      
Loss Contingencies [Line Items]                                      
Infringed patents suit, number of patents                                     5
Infringed patents suit, other party counterclaim, number of patents requested to be delisted                                     1
Number of days provided to delist patent (in days)           14 days                          
Number of patents, paragraph IV certification notice filed                                   1  
Royalty rate for future sale (as a percent)     3.50%                                
Number of days requested for FDA to take action (in days)                 14 days                    
Lupin Lawsuit                                      
Loss Contingencies [Line Items]                                      
Number of lawsuits filed | litigationCase             2     2                  
Infringed patents suit, number of patents                           10          
Number of patents, paragraph IV certification notice filed                             10        
FDA stay of approval period (in months)                           30 months          
Lupin Lawsuit | Xywav                                      
Loss Contingencies [Line Items]                                      
FDA recognition of orphan drug exclusivity, period (in years)                             7 years        
Teva Lawsuit                                      
Loss Contingencies [Line Items]                                      
Infringed patents suit, number of patents                       13              
FDA stay of approval period (in months)                       30 months              
Infringed patents suit, number of patents                         13            
Epidiolex Patent Litigation                                      
Loss Contingencies [Line Items]                                      
Number of lawsuits filed | litigationCase       6 7                            
FDA stay of approval period (in months)               30 months                      
Defitelio Patent Litigation | Subsequent Event                                      
Loss Contingencies [Line Items]                                      
FDA stay of approval period (in months) 30 months